Abstract:CRISPR/Cas9 and single-stranded DNA oligonucleotides (ssODNs) have been used to direct the repair of a single base mutation in human genes. Here, we examine a method designed to increase the precision of RNA guided genome editing in human cells by utilizing a CRISPR/Cas9 ribonucleoprotein (RNP) complex to initiate DNA cleavage. The RNP is assembled in vitro and induces a double stranded break at a specific site surrounding the mutant base designated for correction by the ssODN. We use an integrated mutant eGFP gene, bearing a single base change rendering the expressed protein nonfunctional, as a single copy target in HCT 116 cells. We observe significant gene correction activity of the mutant base, promoted by the RNP and single-stranded DNA oligonucleotide with validation through genotypic and phenotypic readout. We demonstrate that all individual components must be present to obtain successful gene editing. Importantly, we examine the genotype of individually sorted corrected and uncorrected clonally expanded cell populations for the mutagenic footprint left by the action of these gene editing tools. While the DNA sequence of the corrected population is exact with no adjacent sequence modification, the uncorrected population exhibits heterogeneous mutagenicity with a wide variety of deletions and insertions surrounding the target site. We designate this type of DNA aberration as on-site mutagenicity. Analyses of two clonal populations bearing specific DNA insertions surrounding the target site, indicate that point mutation repair has occurred at the level of the gene. The phenotype, however, is not rescued because a section of the single-stranded oligonucleotide has been inserted altering the reading frame and generating truncated proteins. These data illustrate the importance of analysing mutagenicity in uncorrected cells. Our results also form the basis of a simple model for point mutation repair directed by a short single-stranded DNA oligonucleotides and CRISPR/Cas9 ribonucleoprotein complex.

Targeted Gene Correction Directed by Chimeric RNA/DNA Oligonucleotides

Utilization of TALEN and CRISPR/Cas9 Technologies for Gene Targeting and Modification

Efficiency of Chimeraplast Gene Targeting by Direct Nuclear Injection Using a GFP Recovery Assay

Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification.

Targeted Genome Correction by a Single Adenoviral Vector Simultaneously Carrying an Inducible Zinc Finger Nuclease and a Donor Template

Gene repair and transposon-mediated gene therapy

Targeted correction of a chromosomal point mutation by modified single-stranded oligonucleotides in a GFP recovery system.

[Progress on Gene Targeting].

Insertional Mutagenesis by CRISPR/Cas9 Ribonucleoprotein Gene Editing in Cells Targeted for Point Mutation Repair Directed by Short Single-Stranded DNA Oligonucleotides

[Progress in Targeting Gene Therapy].

Gene Correction of Point Mutations Using PolyPurine Reverse Hoogsteen Hairpins Technology

Precise Gene Modification Mediated by TALEN and Single-Stranded Oligodeoxynucleotides in Human Cells.

Application of Zinc Finger Nucleases in Genome Targeting Modification

Oligonucleotide-directed gene-editing technology: mechanisms and future prospects

Gene targeting and its application

Improving the Efficiency of Precise Genome Editing with Site-Specific Cas9-oligonucleotide Conjugates

Gene therapy and gene correction: targets, progress, and challenges for treating human diseases

Nanobiomaterial Vectors for Improving Gene Editing and Gene Therapy

Application of Artificially Induced Double-strand Breaks （DSB） and Triplex-forming Oligonucleotides （TFO） in the Improvement of Gene Targeting Efficiency

[Advances in Genetic Modification Technologies].

Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo